The bacterium Clostridium difficile — otherwise known as C. diff — spreads within intensive care units more than three times as much as previously thought, according to a study published on ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...